300 related articles for article (PubMed ID: 34228539)
21. Treating complicated carbapenem-resistant enterobacteriaceae infections with ceftazidime/avibactam: a retrospective study with molecular strain characterisation.
Krapp F; Grant JL; Sutton SH; Ozer EA; Barr VO
Int J Antimicrob Agents; 2017 Jun; 49(6):770-773. PubMed ID: 28389354
[TBL] [Abstract][Full Text] [Related]
22. Mortality-Related Risk Factors and Novel Antimicrobial Regimens for Carbapenem-Resistant Enterobacteriaceae Infections: A Systematic Review.
Hu Q; Chen J; Sun S; Deng S
Infect Drug Resist; 2022; 15():6907-6926. PubMed ID: 36465807
[TBL] [Abstract][Full Text] [Related]
23. Risk factors for carbapenem-resistant K. pneumoniae bloodstream infection and predictors of mortality in Chinese paediatric patients.
Zhang Y; Guo LY; Song WQ; Wang Y; Dong F; Liu G
BMC Infect Dis; 2018 May; 18(1):248. PubMed ID: 29855274
[TBL] [Abstract][Full Text] [Related]
24. Ceftazidime-Avibactam Use for Klebsiella pneumoniae Carbapenemase-Producing K. pneumoniae Infections: A Retrospective Observational Multicenter Study.
Tumbarello M; Raffaelli F; Giannella M; Mantengoli E; Mularoni A; Venditti M; De Rosa FG; Sarmati L; Bassetti M; Brindicci G; Rossi M; Luzzati R; Grossi PA; Corona A; Capone A; Falcone M; Mussini C; Trecarichi EM; Cascio A; Guffanti E; Russo A; De Pascale G; Tascini C; Gentile I; Losito AR; Bussini L; Corti G; Ceccarelli G; Corcione S; Compagno M; Giacobbe DR; Saracino A; Fantoni M; Antinori S; Peghin M; Bonfanti P; Oliva A; De Gasperi A; Tiseo G; Rovelli C; Meschiari M; Shbaklo N; Spanu T; Cauda R; Viale P
Clin Infect Dis; 2021 Nov; 73(9):1664-1676. PubMed ID: 33618353
[TBL] [Abstract][Full Text] [Related]
25. In Vitro Activities and Inoculum Effects of Ceftazidime-Avibactam and Aztreonam-Avibactam against Carbapenem-Resistant
Kim T; Lee SC; Bae M; Sung H; Kim MN; Jung J; Kim MJ; Kim SH; Lee SO; Choi SH; Kim YS; Chong YP
Antibiotics (Basel); 2020 Dec; 9(12):. PubMed ID: 33334045
[TBL] [Abstract][Full Text] [Related]
26. Combination Regimens for Treatment of Carbapenem-Resistant Klebsiella pneumoniae Bloodstream Infections.
Gomez-Simmonds A; Nelson B; Eiras DP; Loo A; Jenkins SG; Whittier S; Calfee DP; Satlin MJ; Kubin CJ; Furuya EY
Antimicrob Agents Chemother; 2016 Jun; 60(6):3601-7. PubMed ID: 27044555
[TBL] [Abstract][Full Text] [Related]
27. Comparison of Cefepime-Cefpirome and Carbapenem Therapy for Acinetobacter Bloodstream Infection in a Multicenter Study.
Chang YY; Yang YS; Wu SL; Wang YC; Chen TL; Lee YT;
Antimicrob Agents Chemother; 2020 May; 64(6):. PubMed ID: 32179523
[TBL] [Abstract][Full Text] [Related]
28. Efficacy of β-lactam/β-lactamase inhibitors to treat extended-spectrum beta-lactamase-producing Enterobacterales bacteremia secondary to urinary tract infection in kidney transplant recipients (INCREMENT-SOT Project).
Pierrotti LC; Pérez-Nadales E; Fernández-Ruiz M; Gutiérrez-Gutiérrez B; Tan BH; Carratalà J; Oriol I; Paul M; Cohen-Sinai N; López-Medrano F; San-Juan R; Montejo M; Freire MP; Cordero E; David MD; Merino E; Mehta Steinke S; Grossi PA; Cano Á; Seminari EM; Valerio M; Gunseren F; Rana M; Mularoni A; Martín-Dávila P; van Delden C; Hamiyet Demirkaya M; Koçak Tufan Z; Loeches B; Iyer RN; Soldani F; Eriksson BM; Pilmis B; Rizzi M; Coussement J; Clemente WT; Roilides E; Pascual Á; Martínez-Martínez L; Rodríguez-Baño J; Torre-Cisneros J; Aguado JM;
Transpl Infect Dis; 2021 Jun; 23(3):e13520. PubMed ID: 33222379
[TBL] [Abstract][Full Text] [Related]
29. Epidemiology, mortality and risk factors for patients with K. pneumoniae bloodstream infections: Clinical impact of carbapenem resistance in a tertiary university teaching hospital of Beijing.
Zhang G; Zhang M; Sun F; Zhou J; Wang Y; Zhu D; Chen Z; Chen Q; Chang Q; Liu H; Chai W; Pan H
J Infect Public Health; 2020 Nov; 13(11):1710-1714. PubMed ID: 33082112
[TBL] [Abstract][Full Text] [Related]
30. Retrospective Observational Study from a Chinese Network of the Impact of Combination Therapy versus Monotherapy on Mortality from Carbapenem-Resistant
Wang X; Wang Q; Cao B; Sun S; Zhang Y; Gu B; Li B; Liao K; Zhao F; Jin L; Jin C; Yang C; Pei F; Zhang Z; Wang H
Antimicrob Agents Chemother; 2019 Jan; 63(1):. PubMed ID: 30348660
[TBL] [Abstract][Full Text] [Related]
31. Ceftazidime-Avibactam as Salvage Therapy in Pediatric Liver Transplantation Patients with Infections Caused by Carbapenem-Resistant
Wang W; Wang R; Zhang Y; Zeng L; Kong H; Bai X; Zhang W; Liang T
Infect Drug Resist; 2022; 15():3323-3332. PubMed ID: 35782529
[TBL] [Abstract][Full Text] [Related]
32. Ceftazidime-avibactam in the treatment of infections from carbapenem-resistant Klebsiella pneumoniae: Ceftazidime-avibactam against CR-KP infections.
Gu J; Xu J; Zuo TT; Chen YB
J Glob Antimicrob Resist; 2021 Sep; 26():20-25. PubMed ID: 34020072
[TBL] [Abstract][Full Text] [Related]
33. Identifying Effective Durations of Antibiotic Therapy for the Treatment of Carbapenem-resistant Enterobacterales Bloodstream Infections: A Multicenter Observational Study.
Soto CL; Hsu AJ; Lee JH; Dzintars K; Choudhury R; Jenkins TC; McCreary EK; Quartuccio KS; Stohs EJ; Zimmerman M; Tamma PD
Clin Infect Dis; 2024 Jan; 78(1):27-30. PubMed ID: 37584360
[TBL] [Abstract][Full Text] [Related]
34. A Retrospective Analysis of Risk Factors and Outcomes of Carbapenem-Resistant Klebsiella pneumoniae Bacteremia in Nontransplant Patients.
Xiao T; Zhu Y; Zhang S; Wang Y; Shen P; Zhou Y; Yu X; Xiao Y
J Infect Dis; 2020 Mar; 221(Suppl 2):S174-S183. PubMed ID: 32176799
[TBL] [Abstract][Full Text] [Related]
35. Multicenter Clinical and Molecular Epidemiological Analysis of Bacteremia Due to Carbapenem-Resistant Enterobacteriaceae (CRE) in the CRE Epicenter of the United States.
Satlin MJ; Chen L; Patel G; Gomez-Simmonds A; Weston G; Kim AC; Seo SK; Rosenthal ME; Sperber SJ; Jenkins SG; Hamula CL; Uhlemann AC; Levi MH; Fries BC; Tang YW; Juretschko S; Rojtman AD; Hong T; Mathema B; Jacobs MR; Walsh TJ; Bonomo RA; Kreiswirth BN
Antimicrob Agents Chemother; 2017 Apr; 61(4):. PubMed ID: 28167547
[TBL] [Abstract][Full Text] [Related]
36. Predictors of mortality and clinical characteristics among carbapenem-resistant or carbapenemase-producing Enterobacteriaceae bloodstream infections in Spanish children.
Ara-Montojo MF; Escosa-García L; Alguacil-Guillén M; Seara N; Zozaya C; Plaza D; Schuffelmann-Gutiérrez C; de la Vega Á; Fernández-Camblor C; Ramos-Boluda E; Romero-Gómez MP; Ruiz-Carrascoso G; Losantos-García I; Mellado-Peña MJ; Gómez-Gil R
J Antimicrob Chemother; 2021 Jan; 76(1):220-225. PubMed ID: 33038895
[TBL] [Abstract][Full Text] [Related]
37. Effectiveness of ceftazidime-avibactam versus colistin in treating carbapenem-resistant Enterobacteriaceae bacteremia.
Hakeam HA; Alsahli H; Albabtain L; Alassaf S; Al Duhailib Z; Althawadi S
Int J Infect Dis; 2021 Aug; 109():1-7. PubMed ID: 34091006
[TBL] [Abstract][Full Text] [Related]
38. Impact of Penicillin Allergy on Empirical Carbapenem Use in Gram-Negative Bloodstream Infections: An Antimicrobial Stewardship Opportunity.
Al-Hasan MN; Acker EC; Kohn JE; Bookstaver PB; Justo JA
Pharmacotherapy; 2018 Jan; 38(1):42-50. PubMed ID: 29105102
[TBL] [Abstract][Full Text] [Related]
39. Bloodstream Infections due to Carbapenem-Resistant
Shen L; Lian C; Zhu B; Yao Y; Yang Q; Zhou J; Zhou H
Microb Drug Resist; 2021 Feb; 27(2):227-233. PubMed ID: 32584202
[TBL] [Abstract][Full Text] [Related]
40. Clinical characteristics and outcomes of carbapenem-resistant Enterobacterales bacteremia in pediatric patients.
Liu YC; Lu CY; Yen TY; Chang LY; Chen JM; Lee PI; Huang LM
J Microbiol Immunol Infect; 2023 Feb; 56(1):84-92. PubMed ID: 36376217
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
